» Articles » PMID: 38050478

Is Pulmonary Arterial Hypertension Associated with Schistosomiasis Distinct from Pulmonary Arterial Hypertension Associated with Portal Hypertension?

Abstract

Pulmonary arterial hypertension associated with schistosomiasis (SchPAH) and pulmonary arterial hypertension associated with portal hypertension (PoPAH) are lung diseases that develop in the presence of liver diseases. However, mechanistic pathways by which the underlying liver conditions and other drivers contribute to the development and progression of pulmonary arterial hypertension (PAH) are unclear for both etiologies. In turn, these unknowns limit certainty of strategies to prevent, diagnose, and reverse the resultant PAH. Here we consider specific mechanisms that contribute to SchPAH and PoPAH, identifying those that may be shared and those that appear to be unique to each etiology, in the hope that this exploration will both highlight known causal drivers and identify knowledge gaps appropriate for future research. Overall, the key pathophysiologic differences that we identify between SchPAH and PoPAH suggest that they are not variants of a single condition.

Citing Articles

Infection and pulmonary vascular diseases consortium: United against a global health challenge.

Oliveira S, Almodovar S, Butrous G, De Jesus Perez V, Fabro A, Graham B Pulm Circ. 2024; 14(4):e70003.

PMID: 39534510 PMC: 11555293. DOI: 10.1002/pul2.70003.


Treatment algorithm for pulmonary arterial hypertension.

Chin K, Gaine S, Gerges C, Jing Z, Mathai S, Tamura Y Eur Respir J. 2024; 64(4).

PMID: 39209476 PMC: 11525349. DOI: 10.1183/13993003.01325-2024.

References
1.
Ferreira R, Montenegro S, Domingues A, Bandeira A, Silveira C, Leite L . TGF beta and IL13 in Schistosomiasis mansoni associated pulmonary arterial hypertension; a descriptive study with comparative groups. BMC Infect Dis. 2014; 14:282. PMC: 4045919. DOI: 10.1186/1471-2334-14-282. View

2.
Lo N, Bezerra F, Colley D, Fleming F, Homeida M, Kabatereine N . Review of 2022 WHO guidelines on the control and elimination of schistosomiasis. Lancet Infect Dis. 2022; 22(11):e327-e335. DOI: 10.1016/S1473-3099(22)00221-3. View

3.
Sibomana J, Campeche A, Carvalho-Filho R, Correa R, Duani H, Pacheco Guimaraes V . Schistosomiasis Pulmonary Arterial Hypertension. Front Immunol. 2020; 11:608883. PMC: 7758287. DOI: 10.3389/fimmu.2020.608883. View

4.
Nikolic I, Yung L, Yang P, Malhotra R, Paskin-Flerlage S, Dinter T . Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension. Am J Respir Crit Care Med. 2018; 199(7):891-902. PMC: 6444661. DOI: 10.1164/rccm.201807-1236OC. View

5.
Bina J . [Effect of specific therapy on the prevention and reversal of severe forms of schistosomiasis]. Mem Inst Oswaldo Cruz. 1987; 82 Suppl 4:331-2. DOI: 10.1590/s0074-02761987000800062. View